Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted) (2017 - 2025)
Historic EPS (Weighted Average and Diluted) for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to -$1.81.
- Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) fell 2928.57% to -$1.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.93, marking a year-over-year increase of 719.87%. This contributed to the annual value of -$6.3 for FY2024, which is 2361.43% up from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its EPS (Weighted Average and Diluted) stood at -$1.81 for Q3 2025, which was down 2928.57% from -$1.17 recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) ranged from a high of -$1.08 in Q3 2021 and a low of -$3.5 during Q3 2022
- Over the past 5 years, Ultragenyx Pharmaceutical's median EPS (Weighted Average and Diluted) value was -$1.81 (recorded in 2021), while the average stood at -$1.89.
- In the last 5 years, Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) tumbled by 54146.34% in 2021 and then surged by 3721.97% in 2024.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EPS (Weighted Average and Diluted) stood at -$1.79 in 2021, then decreased by 20.67% to -$2.16 in 2022, then skyrocketed by 33.33% to -$1.44 in 2023, then decreased by 3.36% to -$1.49 in 2024, then fell by 21.61% to -$1.81 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.81 for Q3 2025, versus -$1.17 for Q2 2025 and -$1.57 for Q1 2025.